Our
Science
Our pioneering LYTAC (Lysosomal Targeting Chimera) Platform enables targeted degradation of extracellular proteins.
We are utilizing our LYTAC platform to advance a pipeline of first-in-class LYTAC extracellular protein degraders aimed at depleting difficult-to-drug targets, including many that, to date, have been intractable. Our initial pipeline focus is on programs for autoimmune and inflammatory diseases.